Pharmaceuticals, Biotechnology and Life Sciences
FDA) has granted Breakthrough Therapy Designation forSEP-363856, a novel agent for the treatment of people with schizophrenia.
The North America contract research organization (CRO) market isexpected to reach US$ 30,730.1 Mn in 2025 from US$ 16,369.3 Mn in 2017.
Published in the journal Vaccine, data show vaccines targeting theH10N8 and H7N9 influenza viruses to be highly immunogenic andwell-tolerated in healthy adults
The global influenza vaccines market size is expected to surpass USD 6billion by 2025.
ALAMEDA, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24BTX&src=ctag" target="_blank"gt;$BTXlt;/agt; lt;a href="https://twitter.com/hashtag/AMD?src=hash" target="_blank"gt;#AMDlt;/agt;–BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular…
Puma Biotechnology finished first quarter 2019 with Non-GAAP adjusted net income of $8.1M
Acceleron net loss for the first quartere 2019 $38.1M, R&D expenses $32.8
Ocular Therapeutix posts net loss of $17.1 million in the first quarter of 2019
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has launched a generic version of Tarceva®1(erlotinib) tablets, 100 and 150 mg, in the U.S.
Company management and clinical trial investigators will review interim results on the long-term safety and efficacy data of inclisiran from…